Structure Therapeutics Inc. (GPCR)
GPCR Stock Price Chart
Explore Structure Therapeutics Inc. interactive price chart. Choose custom timeframes to analyze GPCR price movements and trends.
GPCR Company Profile
Discover essential business fundamentals and corporate details for Structure Therapeutics Inc. (GPCR) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
3 Feb 2023
Employees
163.00
Website
https://structuretx.comCEO
Raymond C. Stevens
Description
Structure Therapeutics Inc., an international biopharmaceutical company currently in its clinical development phase, is committed to creating and providing groundbreaking oral therapies for various chronic diseases that lack adequate treatment options. The company's primary investigational drug, GSBR-1290, is an orally administered, biased small molecule agonist designed to target the glucagon-like-peptide-1 receptor (GLP-1R). This G-protein-coupled receptor (GPCR) is a recognized and validated therapeutic target for managing both type-2 diabetes mellitus and obesity. Furthermore, Structure Therapeutics is developing other oral small molecule treatments that act on different GPCRs, addressing pulmonary and cardiovascular conditions. For example, ANPA-0073 is a biased agonist aimed at the apelin receptor, a GPCR linked to diseases like idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension. Another compound in their pipeline is LTSE-2578, an oral small molecule that acts as a lysophosphatidic acid 1 receptor antagonist, also being explored for the treatment of IPF. Established in 2016, the company was formerly known as ShouTi Inc. and is headquartered in South San Francisco, California.
GPCR Financial Timeline
Browse a chronological timeline of Structure Therapeutics Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 Aug 2026
EPS estimate is -$0.39.
Earnings released on 7 May 2026
EPS came in at -$0.35 surpassing the estimated -$0.39 by +10.26%.
Earnings released on 26 Feb 2026
EPS came in at -$0.49 falling short of the estimated -$0.35 by -40.00%.
Earnings released on 6 Nov 2025
EPS came in at -$0.37 falling short of the estimated -$0.36 by -2.78%.
Earnings released on 6 Aug 2025
EPS came in at -$0.36 falling short of the estimated -$0.28 by -28.57%.
Earnings released on 8 May 2025
EPS came in at -$0.27 falling short of the estimated -$0.24 by -12.50%.
Earnings released on 27 Feb 2025
EPS came in at -$0.22 surpassing the estimated -$0.23 by +4.35%, while revenue for the quarter reached $1.78m .
Earnings released on 13 Nov 2024
EPS came in at -$0.20 falling short of the estimated -$0.19 by -5.26%.
Earnings released on 8 Aug 2024
EPS came in at -$0.18 surpassing the estimated -$0.23 by +21.74%.
Earnings released on 9 May 2024
EPS came in at -$0.19 surpassing the estimated -$0.21 by +9.52%.
Earnings released on 8 Mar 2024
EPS came in at -$0.17 surpassing the estimated -$0.21 by +19.05%, while revenue for the quarter reached $1.33m .
Earnings released on 14 Nov 2023
EPS came in at -$0.62 falling short of the estimated -$0.29 by -113.79%.
Earnings released on 10 Aug 2023
EPS came in at -$0.60 falling short of the estimated -$0.28 by -114.29%.
Earnings released on 11 May 2023
EPS came in at -$0.25 surpassing the estimated -$0.41 by +39.02%.
Earnings released on 31 Mar 2023
EPS came in at -$1.14 falling short of the estimated -$0.82 by -39.02%.
Earnings released on 30 Sept 2022
EPS came in at -$0.12 .
Earnings released on 30 Jun 2022
EPS came in at -$0.13 .
Earnings released on 31 Mar 2022
EPS came in at -$0.12 .
Earnings released on 31 Dec 2021
EPS came in at -$0.00 .
GPCR Stock Performance
Access detailed GPCR performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
